The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Open accessAbstract
BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). RESULTS: The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen. CONCLUSIONS: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
In the citing paper
“Lipid profile has long been considered among the most important risk factors for CVD in T2DM, and several trials have confirmed that lowering low-density lipoprotein cholesterol (LDL-C) via statins in T2DM was effective in reducing the risk of CVD [81, 82].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [81]
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [7]
In the citing paper
“Because cardiovascular event rates are increased in people with diabetes and established ASCVD, intensive therapy is indicated and has been shown to be of bene fi t in multiple large meta-analyses and randomized cardiovascular outcomes trials (91,99,105,107,108).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established cardiovascular disease in randomized trials (95,107).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“In the PACIFIC study740), which was a multicenter observational registry study on ACS, the incidence rate of fatal and nonfatal myocardial infarction was high, at 35/1,000 person-years, despite approximatively 80% subjects being administered statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“The results of these studies have found that, compared to patients with normal renal function, the risk for cardiovascular events, including cerebrovascular disease, cardiac death, and total mortality increases by 2–3-fold in those with CKD even when the CKD is mild.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“Recent clinical trials in high-risk patients, such as those with acute coronary syndromes or previous cardiovascular events (200–202), have demonstrated that more aggressive therapy with high doses of statins to achieve an LDL cholesterol of <70 mg/dl led to a significant reduction in further events.”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D. J., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,475
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 301–400 of 1,027
Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes
Bangalore, S., Breazna, A., DeMicco, D. A., Wun, C., & Messerli, F. H. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.017 · Cited by 219
Paik, D. T., Chandy, M., & Wu, J. C. (2019) · Pharmacological Reviews · doi:10.1124/pr.116.013003 · Cited by 219
Statins and Liver Toxicity: A Meta‐Analysis
de Denus, S., Spinler, S. A., Miller, K., & Peterson, A. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.6.584.34738 · Cited by 218
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Statin myopathy: A common dilemma not reflected in clinical trials
Fernandez, G., Spatz, E. S., Jablecki, C. K., & Phillips, P. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10073 · Cited by 217
Banach, M., Șerban, M.-C., Sahebkar, A., Mikhailidis, D. P., Ursoniu, S., Ray, K. K., Rysz, J., Toth, P. P., Muntner, P., Moșteoru, S., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0459-4 · Cited by 215
Räber, L., Taniwaki, M., Zaugg, S., Kelbæk, H., Roffi, M., Holmvang, L., Noble, S., Pedrazzini, G., Moschovitis, A., Lüscher, T. F., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu373 · Cited by 215
Morimoto, K., Janssen, W. J., Fessler, M. B., McPhillips, K. A., Borges, V. M., Bowler, R. P., Xiao, Y., Kench, J. A., Henson, P. M., & Vandivier, R. W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7657 · Cited by 215
Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J., & Francis, D. P. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314525531 · Cited by 214
Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography
Xing, L., Higuma, T., Wang, Z., Aguirre, A. D., Mizuno, K., Takano, M., Dauerman, H. L., Park, S., Jang, Y., Kim, C. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.556 · Cited by 214
Rana, J. S., Nieuwdorp, M., Jukema, J. W., & Kastelein, J. J. P. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00594.x · Cited by 212
Tsermpini, E. E., Ilješ, A. P., & Dolžan, V. (2022) · Antioxidants · doi:10.3390/antiox11071374 · Cited by 212
Gaudet, D., Kereiakes, D. J., McKenney, J. M., Roth, E. M., Hanotin, C., Gipe, D. A., Du, Y. E., Ferrand, A.-C., Ginsberg, H. N., & Stein, E. A. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.05.060 · Cited by 211
Pan, W., Pintar, T., Anton, J. M., Lee, V., Vaughn, W. K., & Collard, C. D. (2004) · Circulation · doi:10.1161/01.cir.0000138316.24048.08 · Cited by 211
Mohler, E. R., Ballantyne, C. M., Davidson, M. H., Hanefeld, M., Ruilope, L. M., Johnson, J. L., & Zalewski, A. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.079 · Cited by 210
The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome
Hulten, E., Jackson, J. L., Douglas, K., George, S. V., & Villines, T. C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1814 · Cited by 208
Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy
Silva, M. J., Matthews, M. L., Jarvis, C. I., Nolan, N. M., Belliveau, P., Malloy, M., & Gandhi, P. J. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.02.008 · Cited by 207
Myocardial Infarction—From Atherosclerosis to Thrombosis
Palasubramaniam, J., Wang, X., & Peter, K. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312578 · Cited by 208
Edison, R. J., & Muenke, M. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30386 · Cited by 206
Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 206
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.077 · Cited by 205
Self-citationAtherothrombotic risk stratification and ezetimibe for secondary prevention
Bohula, E. A., Morrow, D. A., Giugliano, R. P., Blazing, M. A., He, P., Park, J.-G., Murphy, S. A., White, J. A., Kesaniemi, Y. A., Pedersen, T. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.070 · Cited by 204
Self-citationKühnast, S., van der Hoorn, J. W. A., Pieterman, E. J., van den Hoek, A. M., Sasiela, W. J., Gusarova, V., Peyman, A., Schäfer, H.-L., Schwahn, U., Jukema, J. W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m051326 · Cited by 204
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 208
Subclinical atherosclerosis: what it is, what it means and what we can do about it
Toth, P. P. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01804.x · Cited by 201
Badimón, L., & Vilahur, G. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06480.x · Cited by 200
Unanswered Questions for Management of Acute Coronary Syndrome
Bugiardini, R., Manfrini, O., & Ferrari, G. M. D. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.13.1391 · Cited by 200
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
Giugliano, R. P., & Sabatine, M. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.001 · Cited by 200
National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand
Tonkin, A. M., Barter, P. J., Best, J. D., Boyden, A. N., Furler, J., Hossack, K., SULLIVAN, D. R., Thompson, P. L., Vale, M. J., Cooper, C., et al. (2005) · Heart Lung and Circulation · doi:10.1016/j.hlc.2005.10.010 · Cited by 197
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Josan, K., Majumdar, S. R., & McAlister, F. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070675 · Cited by 197
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 197
Ballantyne, C. M., Weiss, R., Moccetti, T., Vogt, A., Eber, B., Sosef, F., & Duffield, E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.022 · Cited by 196
Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
Yamamoto, S., Yancey, P. G., Ikizler, T. A., Jerome, W. G., Kaseda, R., Cox, B. E., Bian, A., Shintani, A., Fogo, A. B., Linton, M. F., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.013 · Cited by 197
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000133317.49796.0e · Cited by 196
Intensive Statin Therapy — A Sea Change in Cardiovascular Prevention
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048061 · Cited by 196
Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability
Jinnouchi, H., Sato, Y., Sakamoto, A., Cornelissen, A., Mori, M., Kawakami, R., Gadhoke, N. V., Kolodgie, F. D., Virmani, R., & Finn, A. V. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.05.017 · Cited by 195
Schneeweiß, S., Gagne, J. J., Glynn, R. J., Rühl, M., & Rassen, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.235 · Cited by 195
Shah, B., Newman, J. D., Woolf, K., Ganguzza, L., Guo, Y., Allen, N., Zhong, J., Fisher, E. A. A., & Slater, J. N. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.011367 · Cited by 194
2018 Guidelines for the Management of Dyslipidemia in Korea
Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, B. J., Choi, S., et al. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.78 · Cited by 194
Schubert, J. R., Lindahl, B., Melhus, H., Renlund, H., Leósdóttir, M., Yari, A., Ueda, P., James, S. K., Reading, S. R., Dluzniewski, P. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1011 · Cited by 193
Primary PCI for Myocardial Infarction with ST-Segment Elevation
Keeley, E. C., & Hillis, L. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmct063503 · Cited by 193
Lipid Metabolism, Disorders and Therapeutic Drugs - Review
Vijayakumar, N., & Kim, S. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2021.122 · Cited by 191
Pleiotropic effects of statins
Vasnawala, H., Kavalipati, N., Shah, J., & Ramakrishan, A. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163106 · Cited by 189
Cannon, C. P. (2004) · Cited by 189
Self-citationBaker, W. L., Talati, R., White, C. M., & Coleman, C. I. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.008 · Cited by 188
Statin Safety and Drug Interactions: Clinical Implications
Bottorff, M. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.007 · Cited by 188
Gaba, P., O’Donoghue, M. L., Park, J., Wiviott, S. D., Atar, D., Kuder, J., Im, K., Murphy, S. A., Ferrari, G. M. D., Gaciong, Z. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063399 · Cited by 188
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187
Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease
Tousoulis, D., Psarros, C., Demosthenous, M., Patel, R., Antoniades, C., & Stefanadis, C. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.054 · Cited by 187
Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy
Chatzizisis, Y. S., Koskinas, K. C., Misirli, G., Vaklavas, C., Hatzitolios, A. I., & Giannoglou, G. D. (2010) · Drug Safety · doi:10.2165/11319380-000000000-00000 · Cited by 187
Cardiovascular drug therapy in the elderly: benefits and challenges
Fleg, J. L., Aronow, W. S., & Frishman, W. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.162 · Cited by 186
Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
McTaggart, F., & Jones, P. J. H. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6113-z · Cited by 186
The Current State of Niacin in Cardiovascular Disease Prevention
Lavigne, P. M., & Karas, R. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.030 · Cited by 185
Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease
Virani, S. S., Woodard, L., Ramsey, D. J., Urech, T. H., Akeroyd, J. M., Shah, T., Deswal, A. M., Bozkurt, B., Ballantyne, C. M., & Petersen, L. A. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.09.041 · Cited by 185
Alexopoulos, N. A., Melek, B. H., Arepalli, C. D., Hartlage, G. R., Chen, Z., Kim, S., Stillman, A. E., & Raggi, P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.051 · Cited by 185
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.185752 · Cited by 185
Schwartz, G. G., OLSSON, A. G., Ballantyne, C. M., Barter, P. J., Holme, I., Kallend, D. G., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Shah, P. K., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.09.017 · Cited by 184
Diagnosis and Management of Acute Coronary Syndrome: An Evidence-Based Update
Smith, J., Negrelli, J., Manek, M., Hawes, E. M., & Viera, A. J. (2015) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2015.02.140189 · Cited by 185
Statins and cardioprotection — More than just lipid lowering?
Ludman, A. J., Venugopal, V., Yellon, D. M., & Hausenloy, D. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.01.002 · Cited by 182
The pleiotropic effects of statins
Calabrò, P., & Yeh, E. T. H. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000181482.99067.bf · Cited by 182
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA · doi:10.1001/jama.2012.8439 · Cited by 181
Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, P., Shui, A., McCabe, C. H., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.034 · Cited by 181
Self-citationMendelian randomisation in cardiovascular research: an introduction for clinicians
Bennett, D., & Holmes, M. V. (2017) · Heart · doi:10.1136/heartjnl-2016-310605 · Cited by 181
Who is susceptible to online health misinformation? A test of four psychosocial hypotheses.
Scherer, L. D., McPhetres, J., Pennycook, G., Kempe, A., Allen, L. A., Knoepke, C. E., Tate, C. E., & Matlock, D. D. (2021) · Health Psychology · doi:10.1037/hea0000978 · Cited by 181
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors
Howard, B. V., Best, L. G., Galloway, J. M., Howard, W. J., Jones, K., Lee, E. T., Ratner, R. E., Resnick, H. E., & Devereux, R. B. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1299 · Cited by 180
Katsuki, S., Matoba, T., Nakashiro, S., Sato, K., Koga, J.-I., Nakano, K., Nakano, Y., Egusa, S., Sunagawa, K., & Egashira, K. (2014) · Circulation · doi:10.1161/circulationaha.113.002870 · Cited by 179
Cardiovascular disease and modifiable cardiometabolic risk factors
Cannon, C. P. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80025-1 · Cited by 178
Self-citationBays, H. E., Ose, L., Fraser, N., Tribble, D. L., Quinto, K., Reyes, R., Johnson‐Levonas, A. O., Sapre, A., & Donahue, S. R. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.016 · Cited by 178
Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease
Aday, A. W., & Ridker, P. M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00016 · Cited by 178
Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review
Araújo, J. P., Lourenço, P., Azevedo, A., Friões, F., Rocha‐Gonçalves, F., Ferreira, A., & Bettencourt, P. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.10.030 · Cited by 177
Kazé, A. D., Santhanam, P., Musani, S. K., Ahima, R. S., & Echouffo-Tcheugui, J. B. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.016947 · Cited by 177
Murphy, S. A., Cannon, C. P., Wiviott, S. D., McCabe, C. H., & Braunwald, E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.005 · Cited by 175
Self-citationInflammation as a Therapeutic Target in Atherosclerosis
Nguyen, M. T., Fernando, S., Schwarz, N., Tan, J. T. M., Bursill, C. A., & Psaltis, P. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081109 · Cited by 176
Efferocytosis in atherosclerosis
Adkar, S. S., & Leeper, N. J. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01037-7 · Cited by 182
Bayturan, O., Kapadia, S., Nicholls, S. J., Tuzcu, E. M., Shao, M., Uno, K., Shreevatsa, A., Lavoie, A. J., Wolski, K., Schoenhagen, P., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.050 · Cited by 174
Aim-High Investigators (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.007 · Cited by 174
Nichols, G. A., & Koro, C. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.022 · Cited by 173
Evidence of Pre-Procedural Statin Therapy
Winchester, D. E., Wen, X., Xie, L. X., & Bavry, A. A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.023 · Cited by 173
Risk factor status and vascular events in patients with symptomatic intracranial stenosis
Chaturvedi, S., Turan, T. N., Lynn, M., Kasner, S. E., Romano, J. G., Cotsonis, G., Frankel, M., & Chimowitz, M. I. (2007) · Neurology · doi:10.1212/01.wnl.0000279338.18776.26 · Cited by 173
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-125 · Cited by 172
van der Hoorn, J. W. A., de Haan, W., Berbée, J. F. P., Havekes, L. M., Jukema, J. W., Rensen, P. C. N., & Princen, H. M. G. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.171363 · Cited by 172
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 162
Sassano, A., & Platanias, L. C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.11.036 · Cited by 171
Lipid Levels After Acute Coronary Syndromes
Pitt, B., Loscalzo, J., Yčas, J. W., & Raichlen, J. S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.075 · Cited by 171
Long-Term Use of Cardiovascular Drugs
Rosselló, X., Pocock, S., & Julian, D. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.018 · Cited by 171
Health Insurance and Mortality: Experimental Evidence from Taxpayer Outreach
Goldin, J. S., Lurie, I. Z., & McCubbin, J. (2020) · The Quarterly Journal of Economics · doi:10.1093/qje/qjaa029 · Cited by 170
Coronary Heart Disease in Patients With Diabetes
Berry, C., Tardif, J., & Bourassa, M. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.046 · Cited by 170
Yeganeh, B., Wiecheć, E., Ande, S. R., Sharma, P. K., Moghadam, A. R., Post, M., Freed, D. H., Hashemi, M. M., Shojaei, S., Zeki, A. A., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.007 · Cited by 169
Delahoy, P. J., Magliano, D. J., Webb, K., Grobler, M. P., & Liew, D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.017 · Cited by 169
New insight into dyslipidemia‐induced cellular senescence in atherosclerosis
Xiang, Q., Tian, F., Xu, J. R., Du, X., Zhang, S., & Liu, L. (2022) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12866 · Cited by 169
Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes
Briel, M., Schwartz, G. G., Thompson, P. L., de Lemos, J. A., Blazing, M. A., van Es, G., Kayıkçıoğlu, M., Arntz, H.-R., den Hartog, F. R., Veeger, N. J. G. M., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2046 · Cited by 169
Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists
Fitridge, R., & Thompson, M. M. (2011) · Cited by 168
Morrow, D. A., Wang, Y., Croce, K., Sakuma, M., Sabatine, M. S., Gao, H., Pradhan, A. D., Healy, A. M., Buros, J., McCabe, C. H., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.08.018 · Cited by 168
Self-citationEfficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia
Avis, H. J., Hutten, B. A., Gagné, C., Langslet, G., McCrindle, B. W., Wiegman, A., Hsia, J. A., Kastelein, J. J. P., & Stein, E. A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.042 · Cited by 168
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23438 · Cited by 168
Bonaca, M. P., Morrow, D. A., Braunwald, E., Cannon, C. P., Jiang, S., Breher, S., Sabatine, M. S., Kempf, T., Wallentin, L. C., & Wollert, K. C. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.213512 · Cited by 167
Self-citationEffect of Cinnamon on Glucose Control and Lipid Parameters
Baker, W. L., Gutierrez-Williams, G., White, C. M., Kluger, J., & Coleman, C. I. (2007) · Diabetes Care · doi:10.2337/dc07-1711 · Cited by 167
Fibrates and future PPARα agonists in the treatment of cardiovascular disease
Staels, B., Maes, M., & Zambon, A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1278 · Cited by 169
Sanguigni, V., Pignatelli, P., Lenti, L., Ferro, D., Bellia, A., Carnevale, R., Tesauro, M., Sorge, R. P., Lauro, R., & Violi, F. (2005) · Circulation · doi:10.1161/01.cir.0000153810.81187.7d · Cited by 166
Safety of Aggressive Lipid Management
Davidson, M. H., & Robinson, J. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.067 · Cited by 166
Metadata
- Authors
- Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Pennsylvania (US)
- Université de Montréal (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-08
- Volume
- 350
- Issue
- 15
- Pages
- 1495-1504
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159449551
- Cited by
- 4,938
- References
- 32
- Citations by year
- 2026: 87 · 2025: 84 · 2024: 121 · 2023: 117 · 2022: 120 · 2021: 129 · 2020: 147 · 2019: 163 · 2018: 155 · 2017: 215 · 2016: 178 · 2015: 216 · 2014: 213 · 2013: 215 · 2012: 229
- FWCI
- 442.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- acute coronary syndrome, statins, intensive lipid-lowering therapy, LDL cholesterol, pravastatin, atorvastatin, non-inferiority, major adverse cardiovascular events, revascularization, myocardial infarction, stroke, unstable angina
- MeSH terms
- Atorvastatin, Angina, Unstable, Anticholesteremic Agents, Cardiovascular Diseases, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
